Published in Alzheimers Dement on March 01, 2009
Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID) | NCT00329706
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Design of comprehensive Alzheimer's disease centers to address unmet national needs. Alzheimers Dement (2010) 1.14
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges. Alzheimers Dement (2009) 1.02
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Recruitment of participants for Alzheimer's disease clinical trials: the role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors. Alzheimers Dement (2009) 1.02
Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. Alzheimers Dement (2012) 0.94
Developing a Dementia Research Registry: a descriptive case study from North Thames DeNDRoN and the EVIDEM programme. BMC Med Res Methodol (2011) 0.93
Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. Alzheimers Dement (2009) 0.93
A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research. Alzheimers Dement (2012) 0.81
Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. Prog Neurobiol (2011) 0.80
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A national registry on aging. Alzheimers Dement (2009) 0.78
Economic analysis of opportunities to accelerate Alzheimer's disease research and development. Ann N Y Acad Sci (2014) 0.78
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Facilitating Alzheimer's disease drug development in the United States. Alzheimers Dement (2009) 0.77
Commentary on "a roadmap for the prevention of dementia II: Leon Thal symposium 2008." The megacommunity approach to Alzheimer's disease. Alzheimers Dement (2009) 0.77
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Establishing a national biomarker database: utility and incentives. Alzheimers Dement (2009) 0.77
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Subjective cognitive impairment as an antecedent of Alzheimer's dementia: policy import. Alzheimers Dement (2009) 0.76
Commentary on "Alzheimer's Disease Drug Development and the Problem of the Blood-Brain Barrier". Alzheimers Dement (2009) 0.75
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Alzheimer's disease translational research programs at the National Institute on Aging. Alzheimers Dement (2009) 0.75
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging. Alzheimers Dement (2009) 0.75
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." "Big Asks": what can be changed to increase and speed progress on Alzheimer's disease research and treatment? Alzheimers Dement (2009) 0.75
Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. J Am Geriatr Soc (2014) 0.75
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease. Alzheimers Dement (2009) 0.75
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Innovations in care that advance Alzheimer's disease drug development. Alzheimers Dement (2009) 0.75
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Primary prevention of dementia in Alzheimer's disease: a perspective from prevention research in cardiovascular disease and stroke. Alzheimers Dement (2009) 0.75
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." A national registry to identify a cohort for Alzheimer's disease prevention studies. Alzheimers Dement (2009) 0.75
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Comments from abroad. Alzheimers Dement (2009) 0.75
Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease? Alzheimers Dement (2009) 0.75
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Rationale and recommendations for first evaluating anti-Alzheimer's disease medications in acute brain injury patients. Alzheimers Dement (2009) 0.75
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." A proposal to increase participation in Alzheimer's disease clinical trials. Alzheimers Dement (2009) 0.75
Screening Ability of Subjective Memory Complaints, Informant-Reports for Cognitive Decline, and Their Combination in Memory Clinic Setting. Psychiatry Investig (2017) 0.75
Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology (2007) 12.42
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord (2001) 5.09
2008 Alzheimer's disease facts and figures. Alzheimers Dement (2008) 4.33
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc (2005) 27.90
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage (2006) 25.52
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
Mild cognitive impairment. Lancet (2006) 10.21
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron (2010) 7.87
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA (2008) 7.35
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2010) 7.15
A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 6.84
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med (2003) 6.79
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron (2007) 6.60
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA (2003) 6.34
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2006) 5.58
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Survival after initial diagnosis of Alzheimer disease. Ann Intern Med (2004) 5.52
Health economics and the value of therapy in Alzheimer's disease. Alzheimers Dement (2007) 5.52
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50